doi: 10.1161/CIRCULATIONAHA.105.551457
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:3280-3288.)
© 2005 American Heart Association, Inc.
Heart Failure |
Metabolic Modulation With Perhexiline in Chronic Heart Failure
A Randomized, Controlled Trial of Short-Term Use of a Novel Treatment
From the Department of Cardiology (L.L.), University of Nottingham, Queens Medical Centre, Nottingham, England; Department of Cardiology (R.C., R.T., P.G., L.W., M.F.), University of Birmingham, Queen Elizabeth Medical Centre, Birmingham, England; University Laboratory of Physiology (M.S.-F., K.C.), University of Oxford, Oxford, England; Department of Cardiology (H.A.), Ealing Hospital, London, England; Queen Elizabeth Hospital (J.H.), University of Adelaide, Adelaide, Australia; and University of Wales College of Medicine (A.G.F.), Wales Heart Research Institute, Cardiff, Wales.
Correspondence to Prof Michael Frenneaux, Department of Cardiology, University of Birmingham, Birmingham, B15 2TH UK. E-mail M.P.Frenneaux{at}bham.ac.uk
Received March 28, 2005; revision received July 26, 2005; accepted August 1, 2005.
Background— Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients.
Methods and Results— In a double-blind fashion, we randomly assigned patients with optimally medicated CHF to either perhexiline (n=28) or placebo (n=28). The primary end point was peak exercise oxygen consumption (
O2max), an important prognostic marker. In addition, the effect of perhexiline on myocardial function and quality of life was assessed. Quantitative stress echocardiography with tissue Doppler measurements was used to assess regional myocardial function in patients with ischemic CHF. 31P magnetic resonance spectroscopy was used to assess the effect of perhexiline on skeletal muscle energetics in patients with nonischemic CHF. Treatment with perhexiline led to significant improvements in O2max (16.1±0.6 to 18.8±1.1 mL · kg–1 · min–1; P<0.001), quality of life (Minnesota score reduction from 45±5 to 34±5; P=0.04), and left ventricular ejection fraction (24±1% to 34±2%; P<0.001). Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise. There were no adverse effects during the treatment period.
Conclusions— In patients with CHF, metabolic modulation with perhexiline improved O2max, left ventricular ejection fraction, symptoms, resting and peak stress myocardial function, and skeletal muscle energetics. Perhexiline may therefore represent a novel treatment for CHF with a good safety profile, provided that the dosage is adjusted according to plasma levels.
Key Words: heart failure • metabolism • exercise • fatty acids • glucose
Related Article:
Circulation 2005 112: 3211.
This article has been cited by other articles:
 |
|
 |
|
  L. H. Opie and J. Knuuti The adrenergic-Fatty Acid load in heart failure. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1637 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. Phan, K. Abozguia, G. Nallur Shivu, G. Mahadevan, I. Ahmed, L. Williams, G. Dwivedi, K. Patel, P. Steendijk, H. Ashrafian, et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J. Am. Coll. Cardiol., July 28, 2009; 54(5): 402 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Barba, L. Chavarria, M. Ruiz-Meana, M. Mirabet, E. Agullo, and D. Garcia-Dorado Effect of intracellular lipid droplets on cytosolic Ca2+ and cell death during ischaemia-reperfusion injury in cardiomyocytes J. Physiol., March 15, 2009; 587(6): 1331 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. van Bilsen, F. A. van Nieuwenhoven, and G. J. van der Vusse Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res, February 15, 2009; 81(3): 420 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Duda, K. M. O'Shea, A. Tintinu, W. Xu, R. J. Khairallah, B. R. Barrows, D. J. Chess, A. M. Azimzadeh, W. S. Harris, V. G. Sharov, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction Cardiovasc Res, February 1, 2009; 81(2): 319 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Qanud, M. Mamdani, M. Pepe, R. J. Khairallah, J. Gravel, B. Lei, S. A. Gupte, V. G. Sharov, H. N. Sabbah, W. C. Stanley, et al. Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2098 - H2105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Witteles and M. B. Fowler Reply. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 239 - 240. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Ussher and G. D. Lopaschuk The malonyl CoA axis as a potential target for treating ischaemic heart disease Cardiovasc Res, July 15, 2008; 79(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Luca, A. Mebazaa, G. Filippatos, J. T. Parissis, M. Bohm, A. A. Voors, M. Nieminen, F. Zannad, A. Rhodes, A. El-Banayosy, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes Eur J Heart Fail, February 1, 2008; 10(2): 201 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Witteles and M. B. Fowler Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options J. Am. Coll. Cardiol., January 15, 2008; 51(2): 93 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Merritt, C. Harrison, C. Storey, F. M. Jeffrey, A. D. Sherry, and C. R. Malloy Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR PNAS, December 11, 2007; 104(50): 19773 - 19777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Neglia, A. De Caterina, P. Marraccini, A. Natali, M. Ciardetti, C. Vecoli, A. Gastaldelli, D. Ciociaro, P. Pellegrini, R. Testa, et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3270 - H3278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Lionetti, L. Guiducci, A. Simioniuc, G. D. Aquaro, C. Simi, D. De Marchi, S. Burchielli, L. Pratali, M. Piacenti, M. Lombardi, et al. Mismatch between uniform increase in cardiac glucose uptake and regional contractile dysfunction in pacing-induced heart failure Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2747 - H2756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Scirica, D. A. Morrow, H. Hod, S. A. Murphy, L. Belardinelli, C. M. Hedgepeth, P. Molhoek, F. W.A. Verheugt, B. J. Gersh, C. H. McCabe, et al. Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non ST-Segment Elevation Acute Coronary Syndrome: Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial Circulation, October 9, 2007; 116(15): 1647 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Takahashi, T. Asai, H. Murakami, R. Murakami, M. Tsuzuki, Y. Numaguchi, H. Matsui, T. Murohara, and K. Okumura Pressure Overload-Induced Cardiomyopathy in Heterozygous Carrier Mice of Carnitine Transporter Gene Mutation Hypertension, September 1, 2007; 50(3): 497 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Metra, P. Ponikowski, K. Dickstein, J. J.V. McMurray, A. Gavazzi, C.-H. Bergh, A. G. Fraser, T. Jaarsma, A. Pitsis, P. Mohacsi, et al. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, June 1, 2007; 9(6-7): 684 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fragasso, A. Palloshi, and G. Perseghin Letter by Fragasso et al Regarding Article by Tuunanen et al, "Free Fatty Acid Depletion Acutely Decreases Cardiac Work and Efficiency in Cardiomyopathic Heart Failure" Circulation, May 29, 2007; 115(21): e546 - e546. [Full Text] [PDF]
|
|
|
|
|
|
H. Ashrafian and H. Watkins Reviews of Translational Medicine and Genomics in Cardiovascular Disease: New Disease Taxonomy and Therapeutic Implications: Cardiomyopathies: Therapeutics Based on Molecular Phenotype J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1251 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Neubauer The Failing Heart -- An Engine Out of Fuel N. Engl. J. Med., March 15, 2007; 356(11): 1140 - 1151. [Full Text] [PDF]
|
|
|
|
|
|
E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside J. Am. Coll. Cardiol., November 28, 2006; (2006) j.jacc.2006.08.039v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tuunanen, E. Engblom, A. Naum, K. Nagren, B. Hesse, K. E. J. Airaksinen, P. Nuutila, P. Iozzo, H. Ukkonen, L. H. Opie, et al. Free Fatty Acid Depletion Acutely Decreases Cardiac Work and Efficiency in Cardiomyopathic Heart Failure Circulation, November 14, 2006; 114(20): 2130 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow and M. M. Givertz Modulation of Myocardial Energetics: Emerging Evidence for a Therapeutic Target in Cardiovascular Disease Circulation, November 22, 2005; 112(21): 3218 - 3221. [Full Text] [PDF]
|
|